Infinity Serums.
The secretome, ready to use.
Cells signal. That signalling — the growth factors, cytokines and extracellular vesicles they release — is the most directly translatable output of this platform, and the only one that can be handed to a patient in a bottle. Two topical formats are in development.
Why the secretome is the right first product
A cell therapy requires a procedure, a regulatory pathway, a cold chain and a clinician's time. A topical requires none of those. It is the format that reaches the most patients, the fastest, with the least friction — which is exactly why it is the format worth getting right.
The scientific rationale is not speculative. Published work has examined extracellular vesicles from human trophoblasts acting on skin fibroblasts, and separately the regenerative effect of trophoblast stem cell-derived vesicles on other stem cell populations. Dermal fibroblasts and the follicle are among the most studied targets in the wider extracellular vesicle literature.
What is different here is upstream: the secretome is produced by a source that is developmentally younger, characterised once at depth, and manufactured from a single master line rather than pooled across donors of unknown age.
Extracellular vesicles · secretome fraction
Infinity Serum Dermal
A topical serum formulated around the trophoblast secretome, designed for professional dispensing through provider clinics and for at-home continuation between visits.
Ready-to-use topical serum. No reconstitution, no mixing, no preparation step.
Dermal application. Fibroblast biology is among the most studied targets in the vesicle literature.
Provider clinics first. Approved providers receive early access ahead of any wider release.
In development
Infinity Serum Follicle
A scalp-applied format built on the same secretome science, developed for hair restoration practices and for continuation protocols between in-clinic procedures.
Ready-to-use scalp application with fine-mist delivery. Designed for daily patient compliance.
Follicular environment. Hair is one of the most active areas in the wider vesicle research literature.
Provider clinics first, with patient continuation supply through the supplying practice.
In development
Packaging direction — concept
Built to sit on the shelf it deserves
A clinic dispensing at the top of the market cannot hand a patient something that looks like a supplement. The presentation carries the same argument as the science: deep ink navy, champagne gold, and a mark that reads as a research institution rather than a beauty label.
Product imagery on this page is concept direction produced for the brand programme. Final packaging, formulation and labelling will follow the applicable regulatory requirements in each market at launch.
See the brand systemApproved provider clinics get the serums first.
There is no separate waitlist. Provider clinics are placed on the early-access list at approval and notified before any wider release.
On the regulatory status of secretome products. Secreted and extracted human products — which includes secretome and extracellular-vesicle preparations — are excluded from the U.S. regulatory pathway that covers minimally manipulated human tissue, so that route does not apply to them. No extracellular-vesicle product has been licensed by the FDA, and the agency has taken enforcement action against companies marketing them for therapeutic use. Anything we bring to market in this category will be developed and labelled for its actual permitted use in each jurisdiction, and we will not describe it in structure-or-function terms it cannot support.